摘要
降钙素基因相关肽(calcitonin gene related peptide,CGRP)受体近来成为治疗偏头痛的重要靶点,封闭CGRP受体能使CGRP失活。erenumab是目前唯一一个用于治疗偏头痛的单克隆抗体药物,能特异性地与CGRP受体结合,抑制降钙素基因相关肽所致的偏头痛。基于它在临床试验中的有效性和安全性,2018年5月美国食品和药品管理局(FDA)批准其上市。本文描述了它的基本信息、药理学、临床试验和安全评价,旨在为医生和患者提供有益的参考。
Calcitonin gene related peptide （CGRP） has recently emerged as a promising target for migraine managenlent. Functional blockade of the CGRP receptor inactivates CGRP. By now erenumab is the only human monoclonal antibody which specifically binds to CGRP receptor, thereby inhibiting CGRP-indueed migraine. Based on the clinical efficacy and safety of erenumab, it has been approved by U. S. FDA in May 2018. An overview of erenumab including its general information, pharmacology, and safety value was presented in this article, to provide reference for doctors and patients.
作者
郎丰山
隋忠国
许鹏飞
LANG Fengshan;SUI Zhongguo;XU Pengfei(Department of Pharmacy,the People＇s Hospital of Linqu,Shandong Linqu 262600,China;Department of Pharmacy,the Affiliated Hospital of Qingdao University Medical College,Shandong Qingdao 266003,China)
出处
《中国医药导刊》
2018年第8期468-471,共4页
Chinese Journal of Medicinal Guide
